Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X about a recent article he and his colleagues co-authored, adding:
“Just in The Lancet Oncology
Ph3 CYCLONE 2: Abemaciclib + abiraterone vs. abi did not improve rPFS (primary endpoint) in mCRPC Prostate Cancer.
Higher-risk patients (M1 at dx, Gleason ≥8, PSA) seem to benefit more.”
Title: Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Matthew Smith, Josep Piulats, Tilman Todenhöfer, Jae-Lyun Lee, José Arranz Arija, Laura Mazilu, Arun Azad, Teresa Alonso-Gordoa, Ursula McGovern, Atish Choudhury, Lisa Horvath, Dingwei Ye, Weiqing Han, Hiroyoshi Suzuki, Hiroji Uemura, Rana McKay, Steven Ades, Aude Fléchon, Christopher Pieczonka, Maria S. Fernandes, Maarten Hulstijn, Andrew Lithio, Karim Nacerddine, Neeraj Agarwal
Read the Full Article on The Lancet Oncology
More posts featuring Neeraj Agarwal.